ERP — community confrontation after the JEEP results
This is one entry from the TitrateLab Vendor Graveyard, a dated, primary-source archive of peptide-market shutdowns, exit scams, and enforcement actions. Documented as April 2026. Sources for this entry are named inline below and numbered in full on the parent archive page.
The follow-on wave to the JEEP scandal. After the JEEP endotoxin results made the community-testing-pays culture visible, attention shifted to other high-volume vendors who had been similarly exempt from independent batch-level scrutiny. ERP became the next target. Our editorial position on this entry is more measured than the JEEP entry above — we have less evidence on ERP’s batch-level contamination and more evidence on ERP’s response posture.
ERP (Shanghai ERP Peptide Biotechnology) has been one of the most-recommended international vendors in the 2025-26 GLP-1 grey market, particularly for retatrutide and tirzepatide. They historically posted fresh COAs on a roughly 3-day cadence; the most recent batch in our corpus tested with a −49.5% quantity deviation on Retatrutide (March 25, 2026) (finnrick COA, 2026-03-25), the kind of single-batch outlier that wouldn’t trigger archive-level concern in isolation but contributes to the broader picture.
Timeline: - Through early April 2026 — ERP appears in our corpus as a stable, high-volume vendor with above-average purity but with at least one notable single-batch underdose flagged in March. - April 19, 2026 — A community-published analysis at krysia0430.substack.com/p/the-trouble-with-erp documents what an independent analyst frames as ERP’s “lousy response” to community questions about endotoxin testing on their products. The post is shared on glp1forum.com in a thread titled “JEEP isn’t only endo concern. ERP would like a word.....” - April 19 onwards — The 89-post thread accumulates as the community discusses (a) what specifically ERP said vs. what was being asked, (b) whether independent endotoxin testing should now be expected as table-stakes for any high-volume international vendor, (c) whether ERP’s response pattern (deflection, refusal to publish independent endotoxin data at the batch level) is a leading indicator of a broader quality issue. - Late April 2026 — Our forum-incident detector flags ERP at 8.6× baseline mention volume in the trailing 7-day window vs. the prior 4 weekly windows. The signal is real; the substantive batch-level evidence has not yet emerged the way it did for JEEP.
What we have, what we don’t: - We have: 89-post community discussion, an independent-analyst long-form post, evidence that ERP’s response pattern is being interpreted by serious community members as evasive. - We do not have: a confirmed endotoxin failure on a specific ERP batch the way we have for JEEP. No such result has surfaced. - We do have, and did not check before publishing: 23 third-party certificates on ERP product carrying an endotoxin result, none of them failing. They sit in our own corpus, sourced from finnrick, dated February 26 through June 22, 2026. Sixteen read below the limit of quantitation and seven read low. Every one is tagged by finnrick as submitted by a member of the public rather than by the vendor, a distinction finnrick records explicitly and which separates these from vendor-submitted certificates.
The evidentiary gap that distinguishes the JEEP entry above from this one is therefore narrower than we first described, and it runs the other way on the chemistry: JEEP has a specific batch, a specific lab and specific failing numbers; ERP has an operator-response controversy and a run of independent endotoxin results that pass.
We are no longer flagging ERP on endotoxin. The condition this entry originally set, that independent batch-level endotoxin data should exist, has been met by 23 publicly-submitted third-party certificates spanning February to June 2026, none of which failed. That is the outcome we said would resolve the flag, and we are recording it plainly rather than leaving an adverse posture standing against a condition our own data satisfies.
What remains open is narrower and is not a chemistry question: the response-pattern account in the Krysia write-up, and the separate SS-31 group-test findings recorded further down under Community-warned vendors. Those are documented as one analyst's account and one community group test, and we describe them as such. ERP stays in the catalog and we no longer single it out for elevated scrutiny on the endotoxin question.
Primary sources: the community thread documenting the substack post and ERP’s response posture; the independent-analyst long-form post on substack (linked from the thread).